Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.59 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9387334 | 0.89 | HPGD (0.65) | KDM4ELMNAHPGDHTTSMN1; SMN2 | |
| SCHEMBL10529695 | 0.88 | HPGD (0.62) | KDM4ELMNAHPGDHTTSMN1; SMN2 | |
| SCHEMBL9389616 | 0.86 | HPGD (0.50) | KDM4ELMNAHPGDHTTSMN1; SMN2 | |
| SCHEMBL9385769 | 0.84 | HPGD (0.70) | KDM4ELMNAHPGDHTTSMN1; SMN2 | |
| SCHEMBL9386639 | 0.82 | KDM4E (0.59) | KDM4ELMNAHPGDHTTSMN1; SMN2 | |
| SCHEMBL6014610 | 0.82 | HPGD (1.00) | KDM4ELMNAHPGDHTTSMN1; SMN2 | |
| SCHEMBL13538978 | 0.81 | HPGD (0.74) | KDM4ELMNAHPGDHTTSMN1; SMN2 | |
| SCHEMBL8310231 | 0.81 | HPGD (0.68) | KDM4ELMNAHPGDHTTSMN1; SMN2 | |
| SCHEMBL8866902 | 0.81 | HPGD (0.68) | KDM4ELMNAHPGDHTTSMN1; SMN2 | |
| SCHEMBL17143188 | 0.81 | LMNA (0.58) | KDM4ELMNAHPGDHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956060-B2 | Pyrimidine derivative compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-06-07 | — | — | US | disclosed |
| WO-2010010934-A1 | HETEROCYCLIDENE DERIVATIVE HAVING P-SUBSTITUTED ARYLACETAMIDE | 持田製薬株式会社 (JP) | 2010-01-28 | — | — | WO | disclosed |
| EP-1749827-A1 | ANTI-TUMOR AGENT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-07 | — | — | EP | disclosed |
| US-6756373-B1 | SUCH AS 5-(2-BUTOXY-5-IODO-3-PYRIDINYL)-3-ETHYL-2-(2-METHOXY-ETHYL)-2,6-DIHYDRO-7H -PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; ERECTILE DYSFUNCTION | PFIZER INC. | 2004-06-29 | — | — | US | disclosed |
| EP-0737680-B1 | (Phenylalkylaminoalkyloxyl)-hetero-aryl compounds, processes and intermediates for their preparation and medicaments containing these compounds | SOLVAY PHARM GMBH (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-20030044845-A1 | Novel therapeutic agents for membrane transporters | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-03-06 | — | — | US | disclosed |
| WO-1999064050-A9 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE INC (US) | 2000-04-20 | — | — | WO | disclosed |
| US-5679699-A | ANTIISCHEMIC AGENTS, HEART RATE LOWERING AGENTS | KALI-CHEMIE PHARMA GMBH (DE) | 1997-10-21 | — | — | US | disclosed |
| EP-0737680-A1 | (Phenylalkylaminoalkyloxyl)-hetero-aryl compounds, processes and intermediates for their preparation and medicaments containing these compounds | Kali-Chemie Pharma GmbH (DE) | 1996-10-16 | — | — | EP | disclosed |
| US-5547967-A | HYPOTENSIVE AGENT, ANTIISCHEMIC AGENT | KALI-CHEMIE PHARMA GMBH (DE) | 1996-08-20 | — | — | US | disclosed |
| WO-1991010654-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1991-07-25 | — | — | WO | disclosed |
| EP-0285284-B1 | N-PHENETHYLAMINOALKYL-BENZAMIDE ANTI-ARRHYTHMIA AGENTS | Pfizer Limited (GB) | 1991-05-15 | — | — | EP | disclosed |
| US-4959366-A | Anti-arrhythmic agents | PFIZER INC. (US) | 1990-09-25 | — | — | US | disclosed |
| US-4956382-A | TERTIARY AMINE HETEROCYCLIC SULFONAMIDES | PFIZER INC. (US) | 1990-09-11 | — | — | US | disclosed |
| EP-0281254-B1 | ANTIARRYTHMIC AGENTS | Pfizer Limited (GB) | 1990-01-17 | — | — | EP | disclosed |
| CN-1038451-A | Antiarrhythmics | PFIZER LTD (GB) | 1990-01-03 | — | — | CN | disclosed |
| EP-0285284-A2 | N-phenethylaminoalkyl-benzamide anti-arrhythmia agents | Pfizer Limited (GB) | 1988-10-05 | — | — | EP | disclosed |
| EP-0281254-A1 | Antiarrythmic agents | Pfizer Limited (GB) | 1988-09-07 | — | — | EP | disclosed |
| EP-0245997-A2 | N-substituted p-aminoethylsulphon anilides as antiarrhythmic agents, and intermediates therefor | Pfizer Limited (GB) | 1987-11-19 | — | — | EP | disclosed |
| CN-87103300-A | Antiarrhythmic and preparation method thereof | — | 1987-11-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044845-A1 | Novel therapeutic agents for membrane transporters | SLC47A2, SLC8B1, SLC47A1 | KDM4E 4446/4885LMNA 4372/4885HPGD 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.